Vitality Biopharma Inc(OTCMKTS:VBIO) continues to trend higher in recent months since trading as low as $1.25 back in October of last year. Currently at the $2 mark VBIO has spiked as high as $2.75 in recent months and is looking to move towards previous highs.
VBIO operates in the red hot Marijuana industry that has quickly turned into a multi-billion dollar massive growth market that is sweeping across the Country with many new states legalizing the drug.
Vitality Biopharma Inc(OTCMKTS:VBIO) says it is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. VBIO product pipeline includes Cannabosides – VITA-100 for gastrointestinal disorders, including inflammatory bowel disease and irritable bowel syndrome; Cannabosides – VITA-210 for muscle spasticity in multiple sclerosis and rare white matter disorders; and Cannabosides for epilepsy, schizophrenia, substance abuse, and Huntington’s disease.
Vitality Biopharma has developed a new class of cannabinoid prodrug, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.
Independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease patients experience symptomatic relief, including more than 75% of patients who report improvement in visceral pain and abdominal cramping. Approximately 1.4 million Americans are affected by inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment.
In addition to providing targeted delivery, cannabosides could enable a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief.
To Find out the inside Scoop on VBIO Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Prodrugs are often designed to improve bioavailability when a drug itself is poorly absorbed from the gastrointestinal tract, or to overcome other issues that make molecules unappealing candidates for future development efforts. A prodrug may for instance be used to selectively target a specific tissue or organ, such as the brain or gut, which enables the drug to have a more targeted effect. Prodrugs have been around for a while, with Aspirin, acetylsalicylic acid, first made by Felix Hoffmann at Bayer in 1897, a classic example of a synthetic prodrug of salicylic acid. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.
On January 17 VBIO announced it has submitted an orphan drug designation request for VITA-100 to the U.S. Food & Drug Administration (FDA). Upon approval, VITA-100 would be designated as an orphan drug for the treatment of pediatric ulcerative colitis (UC), a form of pediatric inflammatory bowel disease. The U.S. Orphan Drug Act (ODA) of January 1983 is meant to encourage development of drugs for rare diseases, and review by the FDA’s Office of Orphan Products Development can expedite the evaluation and eventual market approval of products that demonstrate significant promise for the treatment of these conditions.
Vitality Biopharma’s gut-targeted cannabosides enable delivery of THC without psychoactivity or intoxication, which may enable more widespread use of cannabinoids for treatment of pediatric digestive disorders. The Company has already completed studies that demonstrate the efficacy of cannabosides for treatment of preclinical models of colitis. Cannabosides were able to reduce weight loss, decrease damage to the colon, and markedly improve gastrointestinal health compared to the placebo controls.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $44 million market valuation VBIO has minimal cash or revenues; VBIO is Stevia First Corp. STEV reincarnated. The stock has clearly caught the eye of investors with their new class of cannabinoid products, known as cannabosides. The Company has been making headway in the booming pot sector as they develop cannabinoid prodrug pharmaceuticals, as well as unlock the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. We will be updating on VBIO when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with VBIO.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in VBIO either long or short and we have not been compensated for this article.